山东大学学报 (医学版) ›› 2019, Vol. 57 ›› Issue (7): 1-5.doi: 10.6040/j.issn.1671-7554.0.2019.072
• 血液肿瘤精准诊疗及临床转化进展 •
黄晓军
HUANG Xiaojun
摘要： 免疫治疗改变了多种恶性肿瘤的预后及治疗模式,造血干细胞移植是最早应用的免疫治疗之一,是许多血液系统恶性肿瘤的支柱治疗方式。近年新型免疫治疗(如CAR-T、PD-1、NK细胞治疗)在高危恶性血液系统疾病的治疗发展迅猛,受到国内外学者的广泛关注。非移植细胞免疫治疗的优势在于适用于移植失败或有禁忌的患者,以及成为对复发/难治患者可替代的毒性较小的治疗方式。探讨了包括造血干细胞移植在内的细胞免疫治疗在血液系统恶性肿瘤中的应用进展。
中图分类号:
| [1] Hu Y, He GL, Zhao XY, et al. Regulatory B cells promote graft-versus-host disease prevention and maintain graft-versus-leukemia activity following allogeneic bone marrow transplantation [J]. Oncoimmunology, 2017, 6(3): 1284721. [2] Lv M, Zhao XS, Hu Y, et al. Monocytic and promyelocytic myeloid-derived suppressor cells may contribute to G-CSF-induced immune tolerance in haplo-identical allogeneic hematopoietic stem cell transplantation [J]. Am J Hematol, 2015, 90(1): 9-16. [3] Chang YJ, Huang XJ. Use of G-CSF-stimulated marrow in allogeneic hematopoietic stem cell transplantation settings: a comprehensive review [J]. Clin Transplant, 2011, 25(1): 13-23. [4] Huang XJ, Liu DH, Liu KY, et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies [J]. Bone Marrow Transplant, 2006, 38(4): 291-297. [5] Huang XJ, Han W, Xu LP, et al. A novel approach to human leukocyte antigen-mismatched transplantation in patients with malignant hematological disease [J]. Chin Med J(Engl), 2004, 117(12): 1778-1785. [6] Xiao-Jun H, Lan-Ping X, Kai-Yan L, et al. Partially matched related donor transplantation can achieve outcomes comparable with unrelated donor transplantation for patients with hematologic malignancies [J]. Clin Cancer Res, 2009, 15(14): 4777-4783. [7] Wang Y, Liu QF, Xu LP, et al. Haploidentical versus Matched-Sibling Transplant in Adults with Philadelphia-Negative High-Risk Acute Lymphoblastic Leukemia: A Biologically Phase III Randomized Study [J]. Clin Cancer Res, 2016, 22(14): 3467-3476. [8] Wang Y, Liu QF, Xu LP, et al. Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study [J]. Blood, 2015, 125(25): 3956-3962. [9] Wang Y, Chang YJ, Xu LP, et al. Who is the best donor for a related HLA haplotype-mismatched transplant? [J]. Blood, 2014, 124(6): 843-850. [10] Luo Y, Xiao H, Lai X, et al. T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT [J]. Blood, 2014, 124(17): 2735-2743. [11] Wang Y, Wu DP, Liu QF, et al. Donor and recipient age, gender and ABO incompatibility regardless of donor source: validated criteria for donor selection for haematopoietic transplants [J]. Leukemia, 2018, 32(2): 492-498. [12] Luznik L, Engstrom LW, Iannone R, et al. Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation [J]. Biol Blood Marrow Transplant, 2002, 8(3): 131-138. [13] Luznik L, O'Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide [J]. Biol Blood Marrow Transplant, 2008, 14(6): 641-650. [14] Kasamon YL, Luznik L, Leffell MS, et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome [J]. Biol Blood Marrow Transplant, 2010, 16(4): 482-489. [15] Bashey A, Zhang X, Sizemore CA, et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation [J]. J Clin Oncol, 2013, 31(10): 1310-1316. [16] Harris DT, Kranz DM. Adoptive T Cell therapies: A comparison of T Cell receptors and chimeric antigen receptors [J]. Trends Pharmacol Sci, 2016, 37(3): 220-230. [17] Pan J, Yang JF, Deng BP, et al. High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients [J]. Leukemia, 2017, 31(12): 2587-2593. [18] Schuster SJ, Svoboda J, Chong EA, et al. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas [J]. N Engl J Med, 2017, 377(26): 2545-2554. [19] Fry TJ, Shah NN, Orentas RJ, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy [J]. Nat Med, 2018, 24(1): 20-28. [20] Brudno JN, Somerville RP, Shi V, et al. Allogeneic T Cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-Cell malignancies that progress after allogeneic hematopoietic STEM-Cell transplantation without causing graft-versus-host disease [J]. J Clin Oncol, 2016, 34(10): 1112-1121. [21] Chen Y, Cheng Y, Suo P, et al. Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation [J]. Br J Haematol, 2017, 179(4): 598-605. [22] Yifei Cheng, Chenhua Yan, Yu Wang, et al. Donor-derived CD19-targeted T cell infusion eliminates B cell acute lymphoblastic leukemia minimal residual disease with no response to donor lymphocytes after allogeneic hematopoietic stem cell transplantation [J]. Engineering, 2019. [23] Luna JI, Grossenbacher SK, Murphy WJ, et al. Targeting Cancer Stem Cells with Natural Killer Cell Immunotherapy [J]. Expert Opin Biol Ther, 2017, 17(3): 313-324. [24] Sun H, Xu J, Huang Q, et al. Reduced CD160 expression contributes to impaired nk-cell function and poor clinical outcomes in patients with hcc [J]. Cancer Res, 2018, 78(23): 6581-6593. [25] Cong J, Wang X, Zheng X, et al. Dysfunction of natural killer cells by fbp1-induced inhibition of glycolysis during lung cancer progression [J]. Cell Metab, 2018, 28(2): 243-255. [26] Jiang W, Zhang C, Tian Z, et al. hIL-15-gene modified human natural killer cells(NKL-IL15)exhibit anti-human leukemia functions [J]. J Cancer Res Clin Oncol, 2018, 144(7): 1279-1288. [27] Parkhurst MR, Riley JP, Dudley ME, et al. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression [J]. Clin Cancer Res, 2011, 17(19): 6287-6297. [28] Rosenberg SA, Restifo NP, Yang JC, et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy [J]. Nat Rev Cancer, 2008, 8(4): 299-308. [29] Choi I, Yoon SR, Park SY, et al. Donor-derived natural killer cell infusion after human leukocyte antigen-haploidentical hematopoietic cell transplantation in patients with refractory acute leukemia [J]. Biol Blood Marrow Transplant, 2016, 22(11): 2065-2076. [30] Killig M, Friedrichs B, Meisig J, et al. Tracking in vivo dynamics of NK cells transferred in patients undergoing stem cell transplantation [J]. Eur J Immunol, 2014, 44(9): 2822-2834. [31] Curti A, Ruggeri L, Parisi S, et al. Larger size of donor alloreactive nk cell repertoire correlates with better response to nk cell immunotherapy in elderly acute myeloid leukemia patients [J]. Clin Cancer Res, 2016, 22(8): 1914-1921. |
| [1] | 司海朋,张文灿,李乐,周鑫. Kümmell's病的危险因素和诊治研究进展[J]. 山东大学学报 (医学版), 2021, 59(6): 25-32. |
| [2] | 姜宝法,丁国永,刘雪娜. 暴雨洪涝与人类健康关系的研究进展[J]. 山东大学学报 (医学版), 2018, 56(8): 21-28. |
| [3] | 马润美,张翼,王彦文,许丹丹,孙志颖,石婉荧,崔亮亮,李湉湉. 大气颗粒物污染与血糖关系的系统综述[J]. 山东大学学报 (医学版), 2018, 56(11): 27-33. |
| [4] | 李星宇, 梁婧, 李岩. 血管内皮抑素协同肿瘤特异性DC-T细胞的抗肿瘤效应[J]. 山东大学学报（医学版）, 2015, 53(7): 19-23. |
| [5] | 张林1，侯艳红1，张健2，胡静1，张静1. 抗人EGFR/抗CD3双功能抗体治疗胰腺癌的实验研究[J]. 山东大学学报（医学版）, 2014, 52(1): 15-19. |
|
||
